LYEL VS OABI Stock Comparison
Performance
LYEL10/100
10/100
LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.
OABI100/100
100/100
OABI returned 81.85% in the last 12 months. Based on SPY's performance of -13.65%, its performance is above average giving it a score of 100 of 100.
Technicals
LYEL54/100
54/100
LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.
OABI64/100
64/100
OABI receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
LYEL100/100
100/100
LYEL has missed earnings 1 times in the last 20 quarters.
OABI41/100
41/100
OABI has missed earnings 2 times in the last 20 quarters.
Profit
LYEL10/100
10/100
Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.
OABI13/100
13/100
Out of the last 10 quarters, OABI has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
LYEL43/100
43/100
LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
OABI40/100
40/100
OABI has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Lyell Immunopharma, Inc. Common Stock Summary
Nasdaq / LYEL
Healthcare
Biotechnology
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
OmniAb, Inc. Common Stock Summary
Nasdaq / OABI
Healthcare
Biotechnology
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare LYEL to other companies in the same or a similar industry.